Foghorn Therapeutics (FHTX) Other Accumulated Expenses (2020 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Other Accumulated Expenses of $437000.0 for Q1 2026, down 16.92% year-over-year from $526000.0 in Q1 2025, and up 9.25% quarter-over-quarter from $400000.0 in Q4 2025.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $437000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 16.92% year-over-year to $437000.0; the TTM figure through Mar 2026 stood at $437000.0 (down 16.92% YoY), while the FY2025 annual figure was $400000.0, up 39900.0% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $437000.0, up from $400000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $526000.0 in Q1 2025, with the low at $1000.0 in Q4 2024.
- The 5-year median for Other Accumulated Expenses is $286500.0 (2022), against an average of $269625.0.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses tumbled 97.22% in 2024, then soared 39900.0% in 2025.
- Foghorn Therapeutics' Other Accumulated Expenses stood at $318000.0 in 2022, then plunged by 88.68% to $36000.0 in 2023, then sank by 97.22% to $1000.0 in 2024, then jumped by 39900.0% to $400000.0 in 2025, then rose by 9.25% to $437000.0 in 2026.
- Business Quant data shows FHTX's Other Accumulated Expenses at $437000.0 in Q1 2026, $400000.0 in Q4 2025, and $396000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Foghorn Therapeutics | 347.50 Mn | 279.42 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 408,000.00 |
| Mar 31, 2026 | 437,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 396,000.00 |
| Jun 30, 2025 | 392,000.00 |
| Mar 31, 2025 | 526,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 213,000.00 |
| Jun 30, 2024 | 239,000.00 |
| Dec 31, 2023 | 36,000.00 |
| Sep 30, 2023 | 301,000.00 |
| Jun 30, 2023 | 94,000.00 |
| Mar 31, 2023 | 135,000.00 |
| Dec 31, 2022 | 318,000.00 |
| Sep 30, 2022 | 324,000.00 |
| Jun 30, 2022 | 272,000.00 |
| Mar 31, 2022 | 230,000.00 |
| Dec 31, 2021 | 392,000.00 |
| Sep 30, 2021 | 108,000.00 |
| Dec 31, 2020 | 138,000.00 |